3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
20
Neoplasm Metastasis
8
Leukemia, Myeloid, Acute
7
Skin Neoplasms
6
Ovarian Neoplasms
6
Lymphoma, Non-Hodgkin
6
Colorectal Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Leukemia, Lymphocytic, Chronic, B-Cell
5
Uveal Melanoma
4
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Mesothelioma, Malignant
3
Lymphoma, Follicular
3
Lymphoma
3
Lung Neoplasms
3
Leukemia
3
Esophageal Neoplasms
3
Carcinoma, Renal Cell
3
Uterine Cervical Neoplasms
2
Sarcoma
2
Pleural Effusion, Malignant
2
Neuroblastoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Interventions
pembrolizumab
8
Nivolumab
6
Ipilimumab
3
toripalimab
2
atezolizumab
2
Specimen Handling
2
Celecoxib
2
relatlimab
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
camrelizumab
1
avelumab
1
XELOX
1
Neoadjuvant Therapy
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Interleukin-2
1
Induction Chemotherapy
1
Immunotherapy
1
Immune Checkpoint Inhibitors
1
IMM-101
1
E7777 fusion protein
1
Docetaxel
1
Diffusion Tensor Imaging
1
DNA Mismatch Repair
1
DEAE-Dextran
1
Cyclophosphamide
1
Colonoscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Turcot syndrome
×
Interleukin-2
×
1 year
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled